Trump's Bold Move: Will His Plan Really Lower Drug Prices?

President Trump's Executive Order to Lower Drug Prices: A Detailed Analysis On May 12, 2025, President Trump signed a sweeping executive order designed to reduce prescription drug costs in the United States. The order aims to align US government payments for certain medications with the lower prices paid in other countries. This move has sparked significant debate among healthcare experts and policymakers. The executive order is intended to address the long-standing issue of high drug prices in the US, which place a significant financial burden on many American families. According to Christine Romans, NBC News Senior Business Correspondent, "U.S. drug prices are on average two to three times higher than the rest of the world." The plan proposes to achieve lower costs by using the prices of the same drugs in other countries as a benchmark for US government payments. This strategy is not without its critics, who raise concerns about the potential impact on pharmaceutical innovation and the availability of new drugs. The pharmaceutical lobby has historically opposed such measures, arguing that high prices are necessary to fund research and development. However, the Biden administration has already begun negotiating drug prices under Medicare, suggesting that this approach is gaining traction. This initiative, while potentially controversial, represents a significant step towards addressing the affordability crisis facing many Americans reliant on prescription medications.